An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Independence Blue Cross said starting Jan. 1 it will only be covering GLP-1 agonists — commonly sold under brand names like ...

Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

Ozempic and Wegovy, made by Novo, are on track to become the world’s top-selling drugs by 2025. Yet in 2024, ‘Wegovy Wednesday’ had already become one of the biggest weight-loss trends to sweep the ...

Novo's Ozempic is approved by the U.S. Food and Drug Administration (FDA) to treat diabetes, while Wegovy is primarily ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...